QSAR analyses of 3-(4-benzylpiperidin-1-yl)-.N-phenylpropylamine derivatives as potent CCR5 antagonists

Journal of Chemical Information and Modeling

Volumn 45, Issue 5, 2005, Pages 1352-1368

  Roy, Kunal ^a   Leonard, J Thomas ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; DERIVATIVES; ENCODING (SYMBOLS); MATHEMATICAL MODELS; SET THEORY; STATISTICAL METHODS;

BINDING AFFINITY; LINEAR FREE ENERGY RELATED (LFER); MOLECULAR FEATURES; STRUCTURE-ACTIVITY RELATIONSHIP;

AMINES;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; PROPYLAMINE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROPYLAMINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, CCR5;

EID: 26944449698     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci050205x     Document Type: Article

References (40)

1. Campiani, G.; Ramunno, A.; Maga, G.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Morelli, E.; Novellino, E. Nonnucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr. Pharm. Des. 2002, 8, 615-657.
2. http://www.unaids.org/Unaids/EN/Resources/Publications.
3. Jiang, S.; Zhao, Q.; Debanth, A. K. Peptide and non-peptide HTV fusion inhibitors. Curr. Pharm. Des. 2002, 8, 563-580.
4. Sanders, R. W.; Dankers, M. M.; Busser, E.; Caffrey, M.; Moore, J. P.; Berkhout, B. Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41. Retrovirology 2004, 1, 3-13.
5. Markovic, I.; Clouse, K. A. Recent Advances in Understanding the Molecular Mechanisms of HIV-1 Entry and Fusion: Revisiting Current Targets and Considering New Options for Therapeutic Intervention Curr. HIV Res. 2004, 2, 223-234.
6. Mager, P. P. The active site of HIV-1 protease. Med. Res. Rev. 2001, 21, 348-351.
7. Farber, J. M.; Berger, E. A. HIV's response to a CCR5 inhibitor: I'd rather tighten than switch. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 1749-1751.
8. Richman, D. D. HIV chemotherapy. Nature 2001, 410, 995-1001.
9. Kazmierski, W.; Bifulco, N.; Yang, H.; Boone, L.; DeAnda, F.; Watson, C.; Kenakin, T. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg. Med. Chem. 2003, 11, 2663-2676.
10. Tsamis, F.; Gavrilov, S.; Kajumo, F.; Seibert, C.; Kuhmann, S.; Ketas, T.; Trkola, A.; Palani, A.; Clader, J. W.; Tagat, J. R.; McCombie, S.; Baroudy, B.; Moore, J. P.; Sakmar, T. P.; Dragic, T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 2003, 77, 5201-5208.
11. Xu, G.; Kannan, A.; Hartman, T. L.; Wargo, H.; Watson, K.; Turpin, J. A.; Buckheit, R. W., Jr.; Johnson, A. A.; Pommier, Y.; Cushman, M. Synthesis of substituted diarylmethylenepiperidines (DAMPs), a novel class of anti-HIV agents. Bioorg. Med. Chem. 2002, 10, 2807-2816.
12. Stevens, M.; Pannecouque, C.; DeClercq, E.; Balzarini, J. Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV action. Antimicrob. Agents Chemother. 2003, 47, 3109-3116.
13. Debnath, A. K. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors. J. Med. Chem. 2003, 46, 4501-4515.
14. Xu, Y.; Liu, H.; Niu, C.; Luo, C.; Luo, X.; Shen, J.; Chen, K.; Jiang, H. Molecular docking and 3D QSAR studies on l-amino-2-phenyl-4-(piperidin-1-yl)- butanes based on the structural modeling of human CCR5 receptor. Bioorg. Med. Chem. 2004, 12, 6193-6208.
15. Song, M.; Breneman, C. M.; Sukumar, N. Three-dimensional quantitative structure-activity relationship analyses of piperidine-based CCR5 receptor antagonists. Bioorg. Med. Chem. 2004 12, 489-499.
16. Leonard, J. T.; Roy, K. Classical QSAR modeling of CCR5 receptor binding affinity of substituted benzylpyrazoles. QSAR Comb. Sci. 2004, 23, 387-398.
17. Leonard, J. T.; Roy, K. Classical QSAR modeling of HIV-1 reverse transcriptase inhibitor 2-amino-6-arylsulfonylbenzonitriles and congeners. QSAR Comb. Sci. 2004, 23, 23-35.
18. Roy, K.; Leonard, J. T. QSAR modeling of HIV-1 reverse transcriptase inhibitor 2-amino-6-arylsulfonylbenzonitriles and congeners using molecular connectivity and E-sate parameters. Bioorg. Med. Chem. 2004, 12, 745-754.
19. Leonard, J. T.; Roy, K. QSAR modeling of anti-HIV activities of alkenyldiarylmethanes using topological and physiochemical descriptors. Drug Des. Dicovery 2003, 18, 165-180.
20. Roy, K.; Leonard, J. T. QSAR by LFER Model of Cytotoxicity Data of Anti-HIV 5-Phenyl-l-phenylamino-lH-imidazole Derivatives Using Principal Component Factor Analysis and Genetic Function Approximation. Bioorg. Med. Chem. 2005, 13, 2967-2973.
21. Roy, K.; Leonard, J. T. Topological QSAR modeling of cytotoxicity data of anti-HIV 5-phenyl-1-phenylamino-imidazole derivatives using GFA, G/PLS, FA and PCRA techniques. Indian J. Chem. 2005, 44A, accepted.
22. Imamura, S.; Nishikawa, Y.; Ichikawa, T.; Hattori, T.; Matsushita, Y.; Hashiguchi, S.; Kanzaki, N.; Iizawa, Y.; Baba, M.; Sugihara, Y. CCR5 antagonist as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidin-4-carboxamide derivatives. Bioorg. Med. Chem. 2005, 13, 397-416.
23. Imamura, S.; Kurasawa, O.; Nara, Y.; Ichikawa, T.; Nishikawa, Y.; Iida, T.; Hashiguchi, S.; Kanzaki, N.; Iizawa, Y.; Baba, M.; Sugihara, Y. CCR5 antagonist as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-l-yl)propyl]-N,N′-diphenylureas. Bioorg. Med. Chem. 2004, 12, 2295-306.
24. Imamura, S.; Ishihara, Y.; Hattori, T.; Kurasawa, O.; Matsushita, Y.; Sugihara, Y.; Kanzaki, N.; Iizawa, Y.; Baba, M.; Hashiguchi, S. CCR5 Antagonist as Anti-HIV-1 agents. 1. Synthesis and Biological Evaluation of 5-Oxopyrrolidine-3-carboxamide Derivatives. Chem. Pharm. Bull. 2004, 52, 63-73.
25. Hansch, C.; Fujita, T. ρ σ π Analysis: A method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. 1964, 86, 1616-1626.
26. Kubinyi, H. In Methods and Principles in Medicinal Chemistry; Wolff, M. E., Ed.; VCH: Weinhehn, 1993; Vol. 1, pp 497-571.
27. Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR. Hydrophobic, Electronic and Steric Constants; American Chemical Society: Washington, DC, 1995.
28. Franke, R. Theoretical Drug Design Methods; Elsevier: Amsterdam, 1984.
29. Franke, R.; Gruska, A. In Chemometric Methods in Molecular Design; van de Waterbeemd, H., Ed.; VCH: Weinheim, 1995; Vol. 2, pp 113-163.
30. Cerius2 version 4.8 is a product of Accelrys, Inc., San Diego, U.S.A., http://www.accelrys.com/cerius2.
31. Hopfinger, A. J.; Tokarsi, J. S. In Practical Applications of Computer-Aided Drug Design; Charifson, P. S., Ed.; Marcel Dekker: New York, 1997; pp 105-164.
32. Hahn, M. Receptor Surface Models. 1. Definition and Construction. J. Med. Chem. 1995, 38, 2080-2090.
33. Rogers, D.; Hopfinger, A. J. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci. 1994, 34, 854-866.
34. Fan, Y.; Shi, L. M.; Kohn, K. W.; Pommier, Y.; Weinstein, I. N. Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. J. Med. Chem. 2001, 44, 3254-3263.
35. Wold, S. In Chemometric Methods in Molecular Design; van de Waterbeemd, H., Ed.; VCH: Weinheim, 1995; Vol. 2, pp 195-218.
36. SPSS is a statistical software of SPSS Inc., IL.
37. Snedecor, G. W.; Cochran, W. G. Statistical Methods; Oxford & IBH Publishing Co. Pvt. Ltd.: New Delhi, 1967.
38. Wold, S.; Eriksson, L. In Chemometric Methods in Molecular Design; van de Waterbeemd, H., Ed.; VCH: Weinheim, 1995; Vol. 2, pp 312-317.
39. Debnath, A. K. In Combinatorial Library design and Evaluation; Ghose, A. K., Viswanadhan, V. M., Eds.; Marcel Dekker: New York, 2001; pp 73-129.
40. Patrick, G. L. An Introduction to Medicinal Chemistry; Oxford University Press Inc.: New York, 2001.